Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 21pembrolizumab 17Capecitabine 15Nivolumab 13Paclitaxel 12Fluorouracil 12Leucovorin 11Docetaxel 10atezolizumab 7Trastuzumab 7tislelizumab 5Ramucirumab 5durvalumab 4Standard of Care 4Magnetic Resonance Spectroscopy 4Irinotecan 4Cisplatin 4Carboplatin 4zolbetuximab 3zimberelimab 3apatinib 3Specimen Handling 3S 1 (combination) 3Gemcitabine 3Bevacizumab 3trifluridine tipiracil drug combination 2tremelimumab 2trastuzumab deruxtecan 2relatlimab 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Stomach Neoplasms × Remote Patient Monitoring × Clear all
NCT05038254 2025-08-12

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

M.D. Anderson Cancer Center

Phase NA Active not recruiting
750 enrolled
Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡